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overall survival of 26(41%) patients with L.D was 12 months (range (3-
21), and of 6(46%) patients with E.D was 9 months. Median survival of 
the remaining 44(58%) patients, (37(59%) with L.D and 7 patients with 
E.D), with palliative treatment was 2 months in each stage. Difference 
according to treatment is statistically signiﬁcant (p= 0,0055) 
Median Survival from diagnosis of patients with L.D with weight 
loss less than 10% was 11 months and with E.D 2 months (p<0,001). 
Median survival from diagnosis with more than 10% with L.D was 3 
months and with E.D 2 months, difference statistically signiﬁcant (p, 
0003), Log Rank 13,22 1. Median survival from CTRT with L.D was 
16 months and with E.D 9 months (p=.0295). 
Median survival from diagnosis with KPS less than 70% in patients 
with L.D was 5 months and E.D 2 months. and median survival from 
CTRT with L.D was 6 months and median survival with KPS more 
than 70% in LD was 8 months, while in E.D 4 months (p=0.004). 
Median survival from CTRT in L.D was 16 months Range (10-22) and 
with E.D 9 months difference statistically signiﬁcant (p=.0395) 
33% of the patients with, weight loss more than 10% and KPS with less 
than 70% and extension of disease, explains the poor prognosis and low 
survival of this setting. Comparing 6% patients with SCLC of this hos-
pital population, means that about 14%( 160 patients) and about other 
37 patients with E.D, were managed elsewhere. Furthermore 59% of 
patients with L.D of this series did not receive CTRT mostly for costs. 
Conclusions: Selection of patients for treatment with these prognos-
tic factors was not enough to improve survival of LC patients in our 
community. The voluntary lung cancer database registry made possible 
to measure the epidemiology, treatment and follow-up of patients 
with NSCLC and SCLC of the INT. Thus, this system and a national 
database registry for cancer patients, should be useful for better service 
medicine, clinical research and improve patient care in most developing 
countries.
Table 3. Survival data for the entire cohort according to stage
Survival L.D E.D p value
From SCLC diagnosis
CT Median (months) 12 9 .0055
 Paliative 23 2  
 Weight Loss    
  >10% 3 2 .0003
  <10% 11 2 .001
 PSKarnofski    
  >70% 8 4 .004
  <70% 5 2  
From CT 
 Weight Loss    
  <10% 16 5 .0295
  >10% 4 2  
 Karnofsski P S    
  >70% 16 9 .0395
  <70% 6 2  
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Background: Accelerated and hyperfractinated radiotherapy proved 
beneﬁcial in INT0096, but the total dose was low and local recurrence 
was high with higher acute grade (Gr.) 3 + esophagitis. RTOG 0239 
was a phase II trial to improve local control and survival with LSCLC 
with acceptable acute Gr. 3+ esophagitis using accelerated high dose 
TRT and concurrent cisplatin/etoposide. 
Methods: LSCLC pts without pleural effusion, contralateral hilar or 
contralateral supraclavicular nodes and PS 0-1 were enrolled. TRT was 
given to large ﬁelds to 28.8 Gy @1.8 Gy per fraction, 5 days per week 
for 16 fractions followed by BID with large ﬁeld in AM, boost in PM, 
then off-cord boost BID for last 5 days, all at 1.8 Gy per fx for a total 
dose of 61.2 Gy in 34 fx in 5 weeks. Concurrent chemotherapy was 
started with TRT with cisplatin, 60-mg/m2 i.v. Day 1; etoposide, 120-
mg/m2 i.v. day 1; etoposide, 240-mg/m2 p.o. per day or 120 mg/m2 i.v. 
per day on days 2 or 3. Cycles were repeated q.3 wks during and for 2 
cycles after TRT.
Complete responders one month after 4 cycles of chemotherapy were 
asked to participate in a prophylactic cranial irradiation (PCI) study. 
Common toxicity criteria (CTC) 2.0 were used for acute toxicity.
We have analyzed the data to ﬁnd a possible association between a 
patient’s grade 3+ esophagitis status and the percentage of the patient’s 
total esophagus receiving >10 (v10), >20 (v20), and >40 Gy (v40), 
respectively.
Results: The study opened in October 2003 and closed in May, 2006, 
after accruing 72 patients. Acute toxicity information is available on 69 
patients. There were 2 (3%) grade 5 chemotherapy/acute radiotherapy 
toxicities reported [infection with grade 3/4 neutropenia; pulmonary 
(pneumonia)]. Ten patients (14%) experienced acute grade 3 esophagi-
tis/dysphagia toxicities and 1 patient (1%) had acute grade 4-esopha-
gitis/dysphagia toxicity. There were 8 (12 %) grade 3 late radiotherapy 
toxicities reported, of which 1 (2%) was an esophagus toxicity, and 
there were 2 (3%) grade 4 late radiotherapy toxicities [myocardial 
infarction; and lower DLCO] 
All patients’ except for 11 v10, v20, and v40 were reviewed regard-
ing correlation with acute esophagitis. The mean esophageal volume 
percents were 65.1%, 60.2%, and 44.4% for v10, v20, and v40, respec-
tively. To compare v10, v20, and v40 with the status of grade 3 esopha-
gitis, these percentages of esophagus volumes were dichotomized by 
their mean volume percents: at v10, v20, and v40. This data showed 
no statistically signiﬁcant association between the status of grade 3+ 
esophagitis and v10, v20, or v40.
Conclusions: This accelerated high dose TRT with concurrent chemo-
therapy for LSCLC resulted in 16 % acute Gr.3+ esophagitis compared 
to 27% with BID TRT with 45Gy in 3 weeks by INT0096. There were 
3 % grade 5 toxicities. This preliminary report suggests that RTOG-
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0239 has tolerable toxicity. The acute Gr3+ esophageal toxicities were 
not correlated with V10, V20 and V40 possibly because of the small 
number of patients with esophagitis. Pts continue to be followed for the 
primary endpoint of 2-year survival.
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Background: Standard treatment for SCLC has not yet been precisely 
deﬁned. The modalities of chemotherapy may not be the same for all 
patients. There has been a growing interest in heparin since our ﬁrst 
phase III randomized study (Cancer 1994; 74:38-45). Radiotherapy 
must be associated in selected patients, but the results of published 
clinical trials are not predictive for general population outcomes. 
Retrospective, but exhaustive, data analysis from 239 patients treated 
from 1990 to 2002 in a single specialized center emphasized the need 
for optimized treatment.
Methods: 54 computerized clinical and therapeutic items were 
obtained for each patient for statistical analysis. Chemotherapy was 
administered to 235/239 patients: PCDE (cisplatin, cyclophosphamide, 
doxorubicin, etoposide) for 105, CDE for 71, PE (cisplatin or carbopla-
tin, etoposide) for 57, via the intravenous route every four weeks, ex-
cept for two elderly patients in whom chemotherapy was administered 
orally. Chemotherapy was limited to six cycles for complete respond-
ers. Subcutaneous heparin was administered at curative doses cover-
ing the ﬁrst two cycles for 131 patients; 108 did not received heparin 
including contraindications in 16 patients. Limited forms received 
alternating thoracic radiation between the second and ﬁfth chemo-
therapy cycles for 78 patients and concurrent radiotherapy following 
the second cycle for 15 patients. Prophylactic cranial radiation (PCR) 
was administered to 78 patients in complete response and, curative 
cranial radiation to 57 patients with initial or late cerebral metastasis. 
14 patients were operated (surgery systematically associated with three 
or four cycles of chemotherapy). Cases of relapse or progression almost 
received second- or third- line chemotherapy.
Results: are expressed in terms of 2-year survivals, which is much 
more relevant than median survival for this population composed of 
130 limited (l) and 109 extensive (e) forms, with a mean age of 61 
± 11 years, sex ratio 2.7 (73% men), with 226 smokers or ex-smok-
ers. Metastases at diagnosis were mainly located in liver (27%), brain 
(15%) and/or bone (14%). Two-years survival rates were: l forms: 31%, 
e-forms: 7%; PCDE with heparin: 33%, PCDE without heparin: 15%; 
PE with heparin: 27%, PE without heparin: 12%; CDE with heparin: 
2%, CDE without heparin: 4%. 27 patients with limited forms who 
received PCDE + heparin + thoracic radiotherapy + PCR had a 44.2 
(IC 95% = 24.7-62.1)% two-year survival. In a multivariate analysis, 
signiﬁcant prognostic factors were: disease extension: p < 0.0001 (HR 
= 1.945 [1.47-2.58]), patient age: p < 0.006 (HR = 1.03 [1.01-1.04]), 
heparin use: p < 0.018 (HR = 1.4 [1.06-1.91]) and inclusion in a clini-
cal research trial: p < 0.025 (HR = 1.4 [1.05-2.07]).
Conclusions: Although these results can be partially explained by 
obvious clinical bias, the important role of using a combination of all of 
the present modes of therapy in the best patients is demonstrated by the 
outstanding 2-year-survival of 44.2%. On subgroup analysis, PE cannot 
be considered to constitute standard ﬁrst-line chemotherapy. Heparin 
appears to play a very important role in this optimization. In contrast, 
the 7% 2-year survival rate for extensive forms is relatively good for 
such an exhaustive population, probably due to regular treatment of 
relapse. 
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Background: To improve the overall prognosis of limited-disease 
small cell lung cancer (LD-SCLC), we performed a phase II study of 
concurrent administration of irinotecan/cisplatin and thoracic radiation 
therapy (IP+RT) followed by two cycles of consolidation chemotherapy 
with irinotecan/cisplatin (IP).
Methods and Materials: Patients with previously-untreated, histologi-
cally proven LD-SCLC were enrolled in this study. IP+RT consisted of 
2 cycles of irinotecan 35 mg/m2 (days 1, 8 and 15) and cisplatin 60 mg/ 
m2 (day 1) with a 4 week interval. Thoracic radiation therapy of a total 
dose of 59.4 -63 Gy (1.8-2.0 Gy/fx, 5 days/week), was given concur-
rently with the ﬁrst and second chemotherapy cycles. After completion 
of IP+RT, patients without evidence of disease progression received 
an additional 2 cycles of consolidation chemotherapy with irinotecan 
60 mg/m2 (days 1, 8 and 15) and cisplatin 60 mg/m2 (day 1) every 4 
weeks.
Results: Of the 29 patients who started treatment, 25 (86%) completed 
IP+RT. The overall response rate was 88% (95% conﬁdence interval 
[CI], 75 to 100%) including 10 complete responses. Acute toxic effects 
were mainly myelosuppression, esophagitis and diarrhea. Two patients 
died of pneumonitis and sepsis. In one patient, pneumothorax preclud-
ing further therapy was developed during IP+RT. Of the 17 patients 
who went to consolidation phase, all patients completed 2 cycles of IP. 
With a median follow-up duration of 19 months, progression-free and 
overall survival was 8 months (95% CI, 3 to 12 months) and 14 months 
(95% CI, 7 to 21 months), respectively.
Conclusion: IP+RT followed by consolidation IP is an active and toler-
ated regimen for LD-SCLC.
